Companies › Conjupro Biotherapeutics
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CPO301 antibody drug conjugate | – | Phase 1 | Cancer | May 2027 |
| JMT108 Bispecific antibody | – | Phase 1 | Cancer | Jul 2029 |
| SYS6043 Anti-B7-H3 antibody-drug conjugate | B7H3 | Phase 1 | Cancer | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05948865 | CPO301 | Phase 1 | Cancer | Oncology | May 2027 |
| NCT07317505 | JMT108 | Phase 1 | Cancer | Oncology | Jul 2029 |
| NCT07424547 | SYS6043 | Phase 1 | Cancer | Oncology | Dec 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.